 implant human fetal ventral mesencephalon right caudat nucleu advanc parkinson diseas ventral mesencephal tissu singl human fetus week gestat consist striatal site patient advanc parkinson diseas optimum levodopa therapi month immunosuppress signific sustain improv month patient motor fluctuat absent modest group month increas qualiti phase quantiti time specif improv contralater upper limb bradykinesia preoper levodopa requir mean month month deterior baselin rate patient consist follow-up month midgest human fetal tissu improv parkinson diseas individu diseas sever critic trial host factor outcom